Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(1.42)
# 2,730
Out of 4,572 analysts
88
Total ratings
37.97%
Success rate
-11.19%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNMD Mind Medicine (MindMed) | Maintains: Buy | $16 → $14 | $6.22 | +125.08% | 1 | Sep 16, 2024 | |
| BTAI BioXcel Therapeutics | Maintains: Buy | $7 | $0.66 | +957.40% | 5 | Aug 30, 2024 | |
| CLNN Clene | Reiterates: Buy | $94 | $5.03 | +1,768.79% | 3 | Aug 6, 2024 | |
| CMPS COMPASS Pathways | Maintains: Buy | $50 → $48 | $7.48 | +541.71% | 2 | Aug 2, 2024 | |
| CRVO CervoMed | Maintains: Buy | $65 | $16.06 | +304.86% | 3 | Jul 25, 2024 | |
| ITCI Intra-Cellular Therapies | Maintains: Buy | $107 → $113 | $75.48 | +49.71% | 4 | Jun 20, 2024 | |
| CARA Cara Therapeutics | Downgrades: Hold | $10 → $1 | $0.30 | +233.33% | 4 | Jun 13, 2024 | |
| STOK Stoke Therapeutics | Maintains: Buy | $21 → $20 | $15.77 | +26.85% | 3 | May 7, 2024 | |
| GHRS GH Research | Maintains: Buy | $30 → $31 | $7.73 | +301.07% | 3 | May 6, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $154 → $164 | $121.97 | +34.46% | 13 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $26 | $8.73 | +197.82% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $21 → $17 | $7.80 | +118.09% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $33 | $16.65 | +98.20% | 8 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $310 → $305 | $199.41 | +52.95% | 19 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $8.00 | +150.00% | 2 | Sep 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.20 | +2,436.78% | 3 | Sep 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $14 | $6.40 | +118.75% | 3 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $150 | $39.92 | +275.75% | 4 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $17.92 | - | 2 | Jan 31, 2017 |
Mind Medicine (MindMed)
Sep 16, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $6.22
Upside: +125.08%
BioXcel Therapeutics
Aug 30, 2024
Maintains: Buy
Price Target: $7
Current: $0.66
Upside: +957.40%
Clene
Aug 6, 2024
Reiterates: Buy
Price Target: $94
Current: $5.03
Upside: +1,768.79%
COMPASS Pathways
Aug 2, 2024
Maintains: Buy
Price Target: $50 → $48
Current: $7.48
Upside: +541.71%
CervoMed
Jul 25, 2024
Maintains: Buy
Price Target: $65
Current: $16.06
Upside: +304.86%
Intra-Cellular Therapies
Jun 20, 2024
Maintains: Buy
Price Target: $107 → $113
Current: $75.48
Upside: +49.71%
Cara Therapeutics
Jun 13, 2024
Downgrades: Hold
Price Target: $10 → $1
Current: $0.30
Upside: +233.33%
Stoke Therapeutics
May 7, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $15.77
Upside: +26.85%
GH Research
May 6, 2024
Maintains: Buy
Price Target: $30 → $31
Current: $7.73
Upside: +301.07%
Neurocrine Biosciences
May 2, 2024
Maintains: Buy
Price Target: $154 → $164
Current: $121.97
Upside: +34.46%
Apr 30, 2024
Maintains: Buy
Price Target: $36 → $26
Current: $8.73
Upside: +197.82%
Apr 26, 2024
Maintains: Hold
Price Target: $21 → $17
Current: $7.80
Upside: +118.09%
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $16.65
Upside: +98.20%
Feb 20, 2024
Maintains: Buy
Price Target: $310 → $305
Current: $199.41
Upside: +52.95%
Sep 1, 2023
Reiterates: Buy
Price Target: $20
Current: $8.00
Upside: +150.00%
Sep 1, 2023
Reiterates: Buy
Price Target: $5
Current: $0.20
Upside: +2,436.78%
May 10, 2023
Maintains: Buy
Price Target: $10 → $14
Current: $6.40
Upside: +118.75%
Aug 3, 2021
Maintains: Buy
Price Target: $101 → $150
Current: $39.92
Upside: +275.75%
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $17.92
Upside: -